Chronic Lymphocytic Leukemia

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses considerations for treatment strategies in patients with chronic lymphocytic leukemia.

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses sequencing strategies in the treatment of patients with chronic lymphocytic leukemia (CLL).

The European Commission has approved venetoclax for use in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia following at least 1 prior therapy.

The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) reduced the risk of disease progression or death versus obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the treatment landscape of chronic lymphocytic leukemia.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses patient preference in treatment selection for chronic lymphocytic leukemia.

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

Brian T. Hill, MD, PhD, discusses recent advances and regulatory decisions in the treatment of patients with chronic lymphocytic leukemia.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of minimal residual disease (MRD) status in the treatment of patients with chronic lymphocytic leukemia.

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the evolution of therapy in CLL and how physicians are working to balance novel agents with additional modalities.

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).